Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Cost-Effectiveness Research Resource Center

Featured

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Shift to Oral Anti-Cancer Drugs Impacting OCM: Study Shows Rise in Part D Drug Expenses
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
Research Reports
Bone-Modifying Agent Utilization: An Analysis in Patients With Metastatic Cancer and Bone Involvement at an NCI-Designated Cancer Center
04/12/2023
Poorni M. Manohar, MD
Kyle E. Bastys
Micah Tratt
Julie Gralow, MD, FACP, FASCO
Keith D. Eaton, MD, PhD
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the...
04/12/2023
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Editor's Page
The Next 5 Years for Medication Spending
02/06/2023
Winston Wong, PharmD, Editor-in-Chief
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong,...
02/06/2023
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Durvalumab Plus Gemcitabine and Cisplatin for Patients With Advanced Biliary Tract Cancer
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways

Advertisement

News

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Shift to Oral Anti-Cancer Drugs Impacting OCM: Study Shows Rise in Part D Drug Expenses
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Durvalumab Plus Gemcitabine and Cisplatin for Patients With Advanced Biliary Tract Cancer
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Videos

Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
Real-World Efficacy, Safety of First-Line Venetoclax-Based Combination Therapy for AML
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Kishan Patel, MD, Yale School of Medicine
Videos
Atezolizumab Plus Bevacizumab Unlikely Cost-Effective for Advanced HCC
07/01/2021
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses...
07/01/2021
Journal of Clinical Pathways
Videos
Cost-Effectiveness of Adjunctive Osimertinib for EGFR-Positive NSCLC
06/10/2021
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses...
06/10/2021
Journal of Clinical Pathways
David Barrington, MD
Videos
Cost-Effectiveness of Lenvatinib Plus Pembrolizumab for Endometrial Cancer
06/10/2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses...
06/10/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
BDHC thumbnail
Breaking Down Health Care
What Does Quality Mean in Health Care?
07/01/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health...
07/01/2024
Cancer Care Business Exchange
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Tony Mok, MD
Conference Coverage
Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Shift to Oral Anti-Cancer Drugs Impacting OCM: Study Shows Rise in Part D Drug Expenses
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement